ESR1 and breast cancer: Park et al. (25) recently reported that overall survival was longer in estrogen receptor (ER)-positive breast cancer patients with low MST2 expression than in those with high MST2 expression using Kaplan–Meier survival analyses, which implies an important interaction between ER and MST2 in breast cancer.